BiomX Inc. Secures $40M in Pentagon Funding for Phage Therapy Development

BiomX Inc. (NYSE: PHGE), a biotech company with a market cap of just under $13 million, has secured $40 million in non-dilutive funding from the U.S. Defense Health Agency, highlighting the military's interest in combating antibiotic-resistant infections through phage therapy. This funding, administered via the Naval Medical Research Command, supports the development of bacteriophage therapies without the typical shareholder dilution seen in early-stage biotechs. The military's focus is on infections emerging from conflict zones, such as those affecting soldiers in the Ukraine war, where antibiotic-resistant bacteria pose a significant threat.

The company's Phase 2 DANCE trial results for diabetic foot osteomyelitis showed promising outcomes, including a statistically significant reduction in ulcer size and depth, with no serious adverse events reported. These findings are crucial, given the annual $8 billion healthcare burden from diabetic foot infections in the U.S. BiomX's BX004 program for cystic fibrosis also demonstrated potential, with some patients achieving complete clearance of chronic infections after treatment.

Analysts see significant upside potential for BiomX, with price targets suggesting a 2,800-2,900% increase from current trading levels. The company's valuation appears disconnected from its fundamental value, especially when compared to peers like Armata Pharmaceuticals (NYSE: ARMP), which trades at a significantly higher valuation despite having fewer clinical programs. BiomX's unique position, supported by military funding and promising clinical results, positions it as a key player in addressing the global challenge of antibiotic resistance.